Table 1. Patient’s characteristics.
| Variable | Number (%) | Variable | Number (%) |
|---|---|---|---|
| Age (years) | Staging | ||
| Median | 60 | Metastatic | 12 (100%) |
| Range | (37 - 82) | Locally advanced | 0 |
| Sex | Sites of metastases | ||
| Male | 6 (50%) | Hepatic only | 0 |
| Female | 6 (50%) | Extrahepatic | 12 (100%) |
| ECOG | Previous biliary drainage | 2 (17%) | |
| 0 | 4 (33%) | Previous surgery to resect primary tumor | 2 (17%) |
| 1 | 5 (42%) | Previous radiotherapy in the primary tumor | 0 |
| 2 | 1 (08%) | Previous radiotherapy in metastases | 7 (58%) |
| 3 | 2 (17%) | Previous treatment with SIR-spheres | 1 (08%) |
| Smoking history | Previous chemotherapy lines | ||
| Current smoker | 4 (33%) | One | 11 (92%) |
| Former smoker | 1 (08%) | Two | 1 (08%) |
| Never smoker | 7 (58%) | FOLFIRI cycles | |
| Histology | Median | 3 | |
| Adenocarcinoma | 12 (100%) | Range | (1 - 9) |
| Others | 0 | FOLFIRI dose reduction | |
| Primary tumor | Yes | 3 (25%) | |
| Gallbladder | 1 (08%) | No | 9 (75%) |
| Intrahepatic | 9 (75%) | FOLFIRI cycle delays | |
| Extrahepatic | 2 (17%) | Yes | 2 (17%) |
| No | 10 (83%) | ||
| Reason for FOLFIRI discontinuation | |||
| Progressive disease | 11 (92%) | ||
| Adverse events | 1 (08%) |
ECOG, Eastern Cooperative Oncology Group performance status scale; SIR-spheres, microspheres impregnated with 90Ytrium, a beta radiating isotope.